{"entity":{"id":"nct06080776","kind":"trial","name":"SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations","aka":[],"tldr":"A phase 3 trial of SH-1028 tablets in non-small-cell lung cancer, run by Nanjing Sanhome Pharmaceutical, Co., Ltd., now recruiting.","summary":"SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations is a phase 3 interventional study registered as NCT06080776 by Nanjing Sanhome Pharmaceutical, Co., Ltd., with 242 participants planned, started 2023-05-11 and due to reach its primary completion in 2028-02-01. Interventions recorded: SH-1028 tablets and Placebo SH-1028 tablets.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06080776","url":"https://clinicaltrials.gov/study/NCT06080776"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06080776","phase":"3","setting":"A Phase III, Double-blind, Randomised Study of SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","enrolled":242,"outcomes":[]},"route":"/trials/nct06080776/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}